Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957424 · ClinicalTrials.gov registry record · NA
Acceptability of Less Harmful Alternatives to Cigarettes
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT00957424: Completed NA study, sponsored by Roswell Park Cancer Institute.
NCT00957424 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00957424, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking. PURPOSE: This clinical trial is studying the acceptability of less harmful alternatives to cigarettes.
Interventions
- OTHER questionnaire administration
- DRUG nicotine replacement therapy
- OTHER informational intervention
- OTHER internet-based intervention
- BEHAVIORAL telephone-based intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT00957424 record still lists
NCT00957424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which questionnaire administration is the first listed.
NCT00957424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00957424 about?
NCT00957424 is a clinical study titled "Acceptability of Less Harmful Alternatives to Cigarettes". RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking. PURPOSE: This clinical trial is studying the acceptability of less harmful alternatives to cigarettes.
What is the current status of trial NCT00957424?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2009-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00957424?
The interventions under investigation include: questionnaire administration (OTHER), nicotine replacement therapy (DRUG), informational intervention (OTHER), internet-based intervention (OTHER), telephone-based intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00957424?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00957424's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia